Hartmut Göbel
A5028652475- Migraine and Headache Studies
- Ophthalmology and Eye Disorders
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Neurological Complications and Syndromes
- Psychosomatic Disorders and Their Treatments
- Neurosurgical Procedures and Complications
- Pain Mechanisms and Treatments
- Musculoskeletal pain and rehabilitation
- Botulinum Toxin and Related Neurological Disorders
- Neuroscience of respiration and sleep
- Olfactory and Sensory Function Studies
- Biomedical and Chemical Research
- Cardiovascular Syncope and Autonomic Disorders
- Cerebrovascular and genetic disorders
- Traumatic Brain Injury and Neurovascular Disturbances
- Spine and Intervertebral Disc Pathology
- Medical Practices and Rehabilitation
- Complementary and Alternative Medicine Studies
- Body Image and Dysmorphia Studies
- Myofascial pain diagnosis and treatment
- Pain Management and Placebo Effect
- Cerebral Venous Sinus Thrombosis
- Neurological Disorders and Treatments
- Pain Management and Opioid Use
Clinical Research Center Kiel
2015-2025
Schmerzklinik Kiel
2014-2024
Kiel University
1996-2024
Leiden University Medical Center
2021
Springer Nature (Germany)
2020
Massachusetts General Hospital
2008-2020
Harvard University
2020
University of Oslo
2020
University Hospital Cologne
2012-2018
RELX Group (United States)
2018
After the introduction of chronic migraine and medication overuse headache as diagnostic entities in The International Classification Headache Disorders, Second Edition, ICHD-2, it has been shown that very few patients fit into criteria for (CM). system being able to use CM (MOH) diagnosis only after discontinuation proven highly unpractical new data have suggested a much more liberal these diagnoses. Committee has, therefore, worked out inclusive MOH presented this paper. These are included...
Silberstein SD, Olesen J, Bousser M-G, Diener H-C, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J & Steiner TJ on behalf of the International Headache Society. The Classification Disorders, 2nd Edition (ICHD-II)—revision criteria for 8.2 Medication-overuse headache . Cephalalgia 2005; 25:460–465. London. ISSN 0333-1024
AimsMigraine with aura and patent foramen ovale (PFO) are associated. The Percutaneous Closure of PFO in Migraine Aura (PRIMA) trial is a multicentre, randomized to investigate the effect percutaneous closure patients refractory medical treatment.
In an effort to improve migraine management around the world, International Headache Society (IHS) has here developed a list of practical recommendations for acute pharmacological treatment migraine. The are categorized into optimal and essential, in order provide options all possible settings, including those with limited access medications.
This study presents the first account of prevalence headache syndromes, defined according to International Headache Society criteria, in a large representative sample German population; 5000 persons total population were selected from 30,000 households. Subjects requested answer questionnaire about occurrence during their lifetime. The completion rate was 81.2%. Seventy-one point four percent (n = 2902) reported history headache. Twenty-seven five fulfilled criteria for migraine....
<b><i>Objective:</i></b> To evaluate the clinical efficacy of a standardized special root extract from plant <i>Petasites hybridus</i> as preventive therapy for migraine. <b><i>Methods:</i></b> This is three-arm, parallel-group, randomized trial comparing <i>Petasites</i> 75 mg bid, 50 or placebo bid in 245 patients with Eligible met International Headache Society criteria migraine, were ages 18 to 65, and had at least two six attacks per month over preceding 3 months. The main outcome...
The study was designed to compare the response almotriptan in migraine patients who take medication early course of attack with that when is taken after pain has become moderate or severe. A randomized, four-arm, multicentre, multinational, double-blind, placebo-controlled trial (12.5 mg) comparing treatment administration intensity mild and within 1 h headache onset vs. had severe conducted. Of 491 migraineurs enrolled, 403 were evaluable [intention-to-treat population (ITT)]. Their mean...
Botulinum type A toxin (BoNT-A) has antinociceptive and muscle-relaxant properties may help relieve the symptoms of myofascial pain syndrome. In this study we evaluated efficacy tolerability BoNT-A (Dysport®) in patients with syndrome upper back. We conducted a prospective, randomized, double-blind, placebo-controlled, 12-week, multicentre study. Patients moderate-to-severe affecting cervical and/or shoulder muscles (≥10 trigger points, disease duration 6–24 months) were randomized to...
We studied the safety and efficacy of 0 U, 50 100 150 U (five sites), 86 Usub (three sites) botulinum toxin type A (BoNTA; BOTOX); Allergan, Inc., Irvine, CA, USA) for prophylaxis chronic tension-type headache (CTTH). Three hundred patients (62.3% female; mean age 42.6 years) enrolled. For primary endpoint, change from baseline in number TTH-free days per month, there was no statistically significant difference between placebo four BoNTA groups, but a favouring vs. observed (4.5 2.8 tension...
The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent spread of virus. Headache is most common neurological symptom in over 50% those vaccinated. Detailed information about clinical characteristics this form headache has not yet been described. aim study to examine detail headaches occurring after vaccination against COVID-19 with BNT162b2 vaccine for first time. In a multicentre observational cohort study, data on features and...
Background/Objectives: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. Methods: Phenotypes postvaccinal headache recorded in 18,544 participants. The study was launched immediately the start campaign on 12 January 2021 and continued until 1 August 2023. Specific aspects related variables collected via an online questionnaire. clinical characteristics patients vaccinated with...
Cluster headache (CH) is a highly disabling primary disorder with complex underlying mechanism. However, there are currently no effective targeted therapeutic drugs available. Existing medications often have limited efficacy and numerous side effects, which frequently fail to meet clinical needs. This study aims identify potential new targets for CH through proteome-wide mendelian randomization (PWMR). We used PWMR estimate the causal effects of plasma proteins on CH. analysis integrated...
The effects of peppermint oil and eucalyptus preparations on neurophysiological, psychological experimental algesimetric parameters were investigated in 32 healthy subjects a double-blind, placebo-controlled, randomized cross-over design. Four different test applied to large areas the forehead temples using small sponge their effect was evaluated by comparing baseline treatment measure. combination oil, ethanol increased cognitive performance had muscle-relaxing mentally relaxing effect, but...
A1A2 Na<sup>+</sup>/K<sup>+</sup>-ATPase mutations cause familial hemiplegic migraine type 2 (FHM2). The authors identified three putative (D718N, R763H, P979L) and that await validation (P796R, E902K, X1021R). Ten to 20% of FHM cases may be FHM2. have a penetrance about 87%. D718N causes frequent, long-lasting HM, P979L recurrent coma. predispose seizures mental retardation. does not play major role in sporadic HM; only one variant, R383H, occurred 1 24 cases.
The clinical overlap between monogenic Familial Hemiplegic Migraine (FHM) and common migraine subtypes, the fact that all three FHM genes are involved in transport of ions, suggest ion may underlie susceptibility to forms migraine. To test this leading hypothesis, we examined variation 155 using 5257 single nucleotide polymorphisms (SNPs) a Finnish sample 841 unrelated with aura cases 884 non-migraine controls. top signals were then tested for replication four independent case–control...
In collaboration with some of the leading headache centres in Germany, Switzerland and Austria, we have established new guidelines for treatment migraine attacks prevention migraine. A thorough literature research last 10 years has been basis current recommendations. At beginning, present therapeutic novelties, followed by a summary all After an introduction, cover topics like drug therapy practical experience, non-effective medication, prevention, interventional methods, non-medicational...
<h3>Objective:</h3> To apply genetic analysis of genome-wide association data to study the extent and nature a shared biological basis between migraine coronary artery disease (CAD). <h3>Methods:</h3> Four separate methods for cross-phenotype were applied on from 2 large-scale studies (19,981 cases, 56,667 controls) CAD (21,076 63,014 controls). The first quantified overlapping risk variants assessed load loci in migraineurs. Genomic regions then identified by covariance patterns phenotypes...
Abstract Blood pressure (BP) was inconsistently associated with migraine and the mechanisms of BP-lowering medications in prophylaxis are unknown. Leveraging large-scale summary statistics for ( N cases / controls = 59,674/316,078) BP 757,601), we find positive genetic correlations diastolic (DBP, r g 0.11, P 3.56 × 10 −06 ) systolic (SBP, 0.06, 0.01), but not pulse (PP, −0.01, 0.75). Cross-trait meta-analysis reveals 14 shared loci ≤ 5 −08 ), nine which replicate < 0.05) UK Biobank. Five...